Aytu biopharma announces closing of upsized at the market public offering of common stock with full exercise of overallotment and conference call to discuss first-in-class antidepressant exxua(tm) opportunity and commercialization plan

Gross proceeds from offering total $16.6 million. financing led by long-term, healthcare-focused institutional investors, including aytu's largest shareholders nantahala capital management and stonepine capital management, with participation from aytu management and new institutional shareholders.
AYTU Ratings Summary
AYTU Quant Ranking